• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vir Biotechnology Inc (NQ: VIR )

    7.120 +0.170 (+2.45%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 891,751
    Open 7.000
    Bid (Size) 7.100 (1)
    Ask (Size) 7.270 (5)
    Prev. Close 6.950
    Today's Range 6.880 - 7.270
    52wk Range 6.560 - 13.09
    Shares Outstanding 133,976,538
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
    From Vir Biotechnology, Inc.
    Via Business Wire

    Performance

    YTD
    -32.25%
    -32.25%
    1 Month
    -5.32%
    -5.32%
    3 Month
    -18.81%
    -18.81%
    6 Month
    -32.51%
    -32.51%
    1 Year
    -27.05%
    -27.05%

    More News

    Read More
    What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?
    Via Benzinga
    What's Next: Vir Biotechnology's Earnings Preview
    Via Benzinga
    Breaking Down Vir Biotechnology: 6 Analysts Share Their Views
    Via Benzinga
    Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
    From Vir Biotechnology, Inc.
    Via Business Wire
    What You Missed On Wall Street This Past Friday
    Via Talk Markets
    Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
    From Vir Biotechnology Inc.
    Via Business Wire
    Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers
    From Vir Biotechnology, Inc.
    Via Business Wire
    Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
    Via FinancialNewsMedia
    Exposures COVID-19
    Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
    From FN Media Group LLC
    Via GlobeNewswire
    Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
    From Vir Biotechnology, Inc.
    Via Business Wire
    VIR Stock Earnings: Vir Biotechnology Misses EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
    Via Investor's Business Daily
    Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
    From Vir Biotechnology, Inc.
    Via Business Wire
    3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
    Via InvestorPlace
    Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
    From Vir Biotechnology, Inc.
    Via Business Wire
    Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?
    Via Benzinga
    Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.